New Solution for Muscle Loss After Weight Loss Injections

A new drug, apitegromab, shows potential in combating muscle loss experienced by users of popular weight-loss injections such as Ozempic, Wegovy, and Mounjaro. A study published in Nature Medicine suggests this new medication could counteract the phenomenon sometimes referred to as "Ozempic butt," where rapid weight loss leads to a loss of muscle and tissue, particularly in the buttocks.

Research involving 102 adults found that those who received apitegromab alongside obesity drugs maintained their muscle mass while still losing fat. This is significant because muscle tissue is harder to regain than fat. The GLP-1 drugs work by reducing appetite and increasing satiety, leading to reduced food intake and subsequent weight loss. However, the rapid pace of this weight loss is thought to be the primary driver of muscle depletion, rather than the drugs themselves.

“

The study's findings should be considered encouraging early results rather than definitive clinical benefits.

While "Ozempic butt" is not a formal medical diagnosis, plastic surgeons have reported a notable increase in consultations related to this concern. Health experts advise individuals using GLP-1 medications to focus on a healthy diet and incorporate strength training exercises to preserve muscle mass. They also caution that these drugs are not intended for short-term or cosmetic weight loss.

Apitegromab is currently in clinical trials and is administered via injection. Researchers are investigating whether it can be self-administered using a pen device, similar to GLP-1 injections. The drug functions by blocking a protein involved in muscle breakdown and is also being explored for other muscle-wasting conditions. In a six-month trial involving Mounjaro, participants taking apitegromab preserved approximately 1.9 kg more muscle mass compared to those taking a placebo. While the study is considered promising, experts urge caution, describing the findings as "encouraging early results" rather than definitive clinical benefits, and note that the treatment may not be suitable for everyone using GLP-1 drugs.

“

The treatment may not be suitable for everyone using GLP-1 drugs, but it could help some individuals who are losing muscle mass rapidly.